fda approved tirzepatide Novel, Dual-Targeted Treatment for T2D Is US FDA warns online vendors

In the landmark 68-week STEP1 obesity trial, participants on 2.4mg recorded a mean body-weight reduction of 14.9%, versus 2.4% on placebo[1]. 50% lost 15% or more of their body weight, and 69% lost at least 10%[1]

Hormonal Balance : 80% of responders reported regular menstrual cycles after 6 months

Considering that most medications affect the gut microbiome over a more extended period 23 , the design of this study allows us to define more clearly the changes in microbial composition and diversity

For example, triple-target agonists like retatrutide are leading multi-target GLP-1 drugs

When considering semaglutide injections as a method to lose weight, it is important to consult with your doctor first